A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma

Official Title

A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma

Summary:

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC).

Trial Description

Primary Outcome:

  • Overall response rate in chemotherapy-naive participants
Secondary Outcome:
  • Overall response rate in the full study population (chemotherapy-naive and chemotherapy-refractory participants)
  • Duration of response in the chemotherapy-naive and full study populations
  • Disease control rate in the chemotherapy-naive and full study populations
  • Progression-free survival in the chemotherapy-naive and full study populations
  • Overall survival in the chemotherapy-naive and full study populations
  • Number of treatment-emergent adverse events
  • Cmax of INCMGA00012
  • tmax of INCMGA00012
  • Cmin of INCMGA00012
  • AUCt of INCMGA00012

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society